The purpose of the study is to evaluating the acceptability, use and adherence of a pre-exposure prophylaxis (PrEP) program using the co-formulation tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg (TDF/FTC) administered daily by mouth, at four health facilities and one community-based organization providing health care services for MSM and transgender women. This is an Observational, longitudinal, multicenter, open-label study to evaluate the acceptability, use and adherence to TDF/FTC-based PrEP in volunteer men who have sex with men and transgender women at substantial high risk of acquiring HIV, who were prescribed for PrEP , following the clinical guidelines to prevent HIV infection of the U.S. Centers for Disease Control and Prevention (2014) and the World Health Organization (2015). Follow-up: Participants will be followed for 96 weeks (approximately two years) after the start of prophylactic treatment. Implementation Target Population: Adults (≥18 years of age), without HIV infection diagnosis, and who were prescribed with PrEP and have a substantial risk of acquiring HIV infection according to the international guidelines for HIV prevention. Sample Size: 1,000 participants Implementation Sites: 1. Asociación Civil Impacta Salud y Educación, Barranco study site 2. Asociación Civil Impacta Salud y Educación, San Miguel study site 3. Asociación Civil Selva Amazónica, ACSA study site 4. Asociación Vía Libre, Vía Libre study site 5. Espacio Común, Epicentro study site Primary Objectives: 1. Describing the acceptability and its socio-demographic and sexual behavior correlates for the use of PrEP. 2. Evaluate the persistence of the use of PrEP and its correlates with risk behaviors 3. Evaluating the adherence to the PrEP using self-reporting and pill counts Secondary Objectives: 1. Describing the changes over time in risky sexual behavior among study participants. 2. Describing the number of participants who acquire HIV infection. 3. Evaluate the deviation of the indication of use of PrEP through self- reporting of its sale or sharing with third parties.
Age range
18 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Acceptability, use and adherence of a pre-exposure prophylaxis (PrEP) program using the co-formulation tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg (TDF/FTC) administered daily by mouth,
Timeframe: through study completion, an average of 4 years